You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / CIPLA

CIPLA
Intrinsic Value | Fundamental Analysis

Returns | 1W : 3.3% , 1M : 25.1%,1Y : 62.3%
BOM : 500087     NSE : CIPLA    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Apr 22,2021
Price(EOD): Rs. 944.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 76,161.83 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
CIPLA 3.3% 25.1% 62.3%
SUN PHARMACEUTICAL INDUSTRIES 1.2% 11.4% 36.3%
DR REDDYS LABORATORIES 7.4% 23.5% 34.1%
DIVIS LABORATORIES -0.8% 14.8% 61.7%
BIOCON -1.2% 2.6% 12.1%
AUROBINDO PHARMA 8.6% 23.1% 82.7%
LUPIN 1.1% 6.1% 34.7%
TORRENT PHARMACEUTICALS 0.4% 8.8% 11.6%
CADILA HEALTHCARE 9.6% 31.5% 67%

FUNDAMENTAL ANALYSIS OF CIPLA

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than CIPLA Premium


VALUATION OF CIPLA

 
Valuation Score
RatioValue
P/E
P/B
P/S
49.24
P/E Calculated based on EPS of 19.18
[ Mar2020 - Consolidated Results ]

4.85
P/B Calculated based on Book Value of 194.85
[ Mar2020 - Consolidated Results ]

4.35
P/S Calculated based on Revenues of 17489.1 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than CIPLA Premium


FAIR VALUE OF CIPLA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
135%
22%
25%

SHARE PRICE MOMENTUM OF CIPLA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0
0
0.01
-
0.18
0.29
0.29
0.25
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
0 %
As on : Sep2020

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated 1 Qtr Growth 4 Qtr Growth
Revenue
Op Profit
EBIDT
Net Income
2.59%
7.14%
10.35%
13.7%
18.25%
58.69%
101.71%
112.83%
QtrlyTrend
8
Latest Qtr: Dec2020

CIPLA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 3.7% 15.3% 56.9%
S&P BSE MOMENTUM 0.5% 10.6% 36%
S&P BSE ALLCAP -0.8% -0.3% 59.7%
MFG -0.8% 1.8% 44.1%
S&P BSE GREENEX -0.9% 2.2% 63.5%
S&P BSE 500 -0.9% -0.4% 58.8%
S&P BSE 250 LARGEMIDCAP -0.9% -0.4% 57.2%
S&P BSE 200 -1% -0.5% 56.9%
S&P BSE 100 ESG INDEX -1% -0.6% 62.2%
S&P BSE LARGE MIDCAP -1% -0.7% 55.6%
S&P BSE DIVIDEND STABILITY -1.1% -0.6% 48.4%
S&P BSE CARBONEX -1.1% -1% 56.2%
S&P BSE 100 LARGECAP TMC -1.1% -0.7% 53.9%
S&P BSE 100 -1.1% -0.9% 54.3%
S&P BSE LARGECAP -1.2% -0.9% 53.7%
S&P BSE SENSEX50 -1.2% -0.9% 54.1%
NSE Indices1W1M1Y
NIFTY PHARMA 3% 16.2% 46.8%
NIFTY ALPHA LOW-VOLATILTY 30 0.4% 4.3% 39.7%
NIFTY 100 EQUAL WEIGHT -0.3% 1.2% 60.5%
NIFTY 500 -0.9% -0.4% 58.3%
NIFTY LARGE MIDCAP 250 -0.9% -1.7% 65%
NIFTY 200 -1% -0.4% 55.9%
NIFTY 100 -1.1% -0.7% 53.2%
NIFTY 50 -1.2% -1% 54.4%

FAQ [Frequently Asked Questions]


Is CIPLA good for long term investment?

As on 22-Apr-2021, the Fundamentals of CIPLA are Strong and hence it's good for long term investment! See Financial Performance of CIPLA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is CIPLA UnderValued or OverValued?

As on 22-Apr-2021, CIPLA is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of CIPLA ?

As on 22-Apr-2021, the Intrinsic Value of CIPLA is Rs. 752.48 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 402.52
Fair Value [Median EV / Sales Model] : Rs. 774.85
Fair Value [Median Price / Sales Model] : Rs. 752.48
Median Fair Value of CIPLA : Rs. 752.48

Is CIPLA trading at a Premium or Discount?

As on 22-Apr-2021, CIPLA is trading at a Premium of 25% based on the Median Intrinsic Value!

Is it right time to buy CIPLA shares?

As on 22-Apr-2021, CIPLA is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Financial Performance of Industry Peers of CIPLA?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of BIOCON LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD
Financials of ALKEM LABORATORIES LTD

What are the Frequent Comparisons with CIPLA?

CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD
CIPLA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ALKEM LABORATORIES LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z